SciSparc Ltd.:N2off股东批准与SciSparc控股子公司Mitocarex合并,该药物发现公司专注于耐药性癌症研究,包括胰腺癌和非小细胞肺癌
SciSparc Ltd.:N2off股东批准与SciSparc控股子公司Mitocarex合并,该药物发现公司专注于耐药性癌症研究,包括胰腺癌和非小细胞肺癌
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.